FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
March 9, 2016
HeartCheck™ PEN Devices now available in over 850 Canadian Retail Pharmacies
Toronto, Canada – CardioComm Solutions, Inc. (TSX-V:EKG) (“CardioComm Solutions” or the “Company”), a global provider of consumer and medical electrocardiogram (“ECG”) acquisition and management software solutions , confirmed today that Rexall and Shoppers Drug Mart pharmacies, Canada’s largest retail pharmacy chains, have renewed their listing for over-the-counter (“OTC”) sales of the HeartCheck™ ECG PEN in select locations for 2016.
The Company confirms that the number of pharmacies that have received HeartCheck™ ECG PEN orders in 2016 has increased from 647 pharmacies to over 850 locations nationally. Both retailers have placed the HeartCheck™ ECG PEN in the diagnostic device OTC section. The Company also continues to provide inventory to independently operated and privately owned pharmacies.
The HeartCheck™ ECG PEN has passed regulatory reviews by both Health Canada and the US Food and Drug Administration as the only ECG displaying personal heart monitoring device approved for sale directly to consumers without a physician’s prescription or guidance. Pharmacy-based sales are targeting consumers, and their family, over the age of 40 years who are interested in the preservation of their heart health as well as those at risk for developing arrhythmias due to underlying conditions, especially prior heart attack, prior cardiac surgery, high blood pressure, high cholesterol, heart failure and diabetes. The devices are specifically aligned for the detection of atrial fibrillation (AF) and to track for ECG signs for risk of sudden cardiac death traits such as medication induced prolonged QT intervals.
The HeartCheck™ ECG PEN is used to take a 30 second ECG recording to monitor for the presence or absence of an arrhythmia. The recorded ECGs are to be uploaded to CardioComm Solutions’ managed cloud SMART Monitoring ECG service where the Company’s proprietary GEMS™-based ECG software is used to review and provide ECG interpreted reports back to PEN users. An advantage of the HeartCheck™ ECG PEN is that it is a small and fully contained ECG device that can independently record, save, replay and transfer recorded ECGs to a computer. A market advantage of the HeartCheck™ ECG PEN over other ECG monitors is that in addition to the usual handheld recordings (Lead I), the device can be held in the right hand and pressed against the left side of the chest or ribs to record a Lead II ECG which is preferred by physicians when screening for arrhythmias.
The Company confirms that it continues to fulfil monthly orders and that physicians are now starting to prescribe the HeartCheck™ ECG PEN to their patients, helping to increase pharmacy sales. CardioComm Solutions will provide further updates on the HeartCheck™ Program and participating pharmacy locations at http://www.theheartcheck.com.
To learn more about CardioComm Solutions’ products please contact the Company at email@example.com.
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.